

#### **Illinois Prescription Monitoring Program**

**Update - July 2023** 



Due to the recent IDFPR e-mail communication sent to all Illinois Controlled Substance License holders regarding the requirement to register for an ILPMP account, ILPMP is currently experiencing a higher-thannormal volume of e-mails. Please be advised that communication will be delayed. Please note: If you already have an existing ILPMP account with Illinois State License number, you do not need to register again. Please review the FAQs for detailed information.

**IDFPR Letter** 



Subscribe to follow us @ILPMP on YouTube

View as Webpage

## PMPnow Program Director attends CDC Overdose Data to Action Conference



The CDC, in conjunction with ASTHO, held the "Overdose Data to Action" (OD2A) meeting June 7-9, 2023 in Atlanta, GA. The attendees at this conference were from the CDA, ASTHO, state departments of public health, local and Indian Territory health departments, Prescription Drug Monitoring Programs as well as other grant recipients from the CDC/ASTHO programs. Jen Erickson, MHA, MS, PMPnow Program Director for the ILPMP attended this meeting. Jen and Jackie DeNardo, RHIA from the ILPMP developed a Poster Presentation – Integration in Illinois. During the scheduled poster session attendees were able to view and discuss the posters with the presenters. In addition to the scheduled session, the posters were displayed in the major walkways for the two day conference where the attendees could view at anytime.

Overdose Data to Action (OD2A) supports jurisdictions in collecting high quality, comprehensive, and timely data on nonfatal and fatal overdoses and in using those data to inform prevention and response efforts. OD2A focuses on understanding and tracking the complex and changing nature of the drug overdose epidemic and highlights the need for seamless integration of data into prevention strategies. Included as part of these grant programs are opportunities such as this conference for awardees to learn from each other and share the successes of their representatives through these grant funds.

# A new nasal spray to reverse fentanyl and other opioid overdoses gets FDA approval

#### Opvee (nalmefene) nasal spray 2.7mg

- Pure Opioid antagonist approved May '23, available Oct '23
- Emergency treatment of opioid overdose for age 12 years and older



#### Compared to naloxone:

- Much longer 4 hour duration, vs 30-90min
- 4x higher potency at mu-opioid receptor
- Similar onset and time to peak
- Less need for multiple doses
- Prolonged duration of opioid withdrawal
- Less well known and less widely available



**More Information** 

# Amendments to 77 Ill. Adm. Code 2081 - Adopted


Effective 7/7/2023, amendments to 77 Illinois Administrative Code 2081 have been adopted. See published Rules in the July 21 version of the Illinois Register.

# University of Illinois Chicago College of Pharmacy to Offer Free Opioid Analgesic REMS CE

**FREE** Continuing Education Programs for Healthcare Providers, provided through UIC – Illinois ADVANCE 15-20 minute Academic Detailing Virtual Visits (Each program approved for 0.5 contact hours. CME, CNE, CPE)

- Meets DEA requirements for opioid education
- Fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement issued by the FDA.

**More Information** 



To learn more about our program visit https://academicdetail.pharmacy.uic.edu/



#### **Educational Resources**

## VIRTUAL LUNCH AND LEARN SERIES

#### Nonpharm Management of Pain

August 24th 12:00PM CST

Presented by:

LAURA MEYER-JUNCO, PHARMD, BCPS, CPE CLINICAL ASSISTANT PROFESSOR, UNIVERSITY OF ILLINOIS



Moderated by:

Chris Herndon, PharmD Professor, SIUE

This webinar is not approved for continuing education



## **NEW Webinar: Continuing Medical Education**

#### **Benefits of a Designee**



College of Pharmacy

Webinar

- Describe the ILPMP program and registration process
- Explain how a prescriber can assign a designee
- Identify the capabilities and responsibilities of a prescriber and designee within the ILPMP
- Discuss the importance and benefits of assigning designee(s)
- 1.0 contact hour CME

The ILPMP collects and tracks controlled substances and other drugs of interest, including:

- Naltrexone
- Naloxone
- Butalbital/Acetaminophen/Caffeine
- Muscle Relaxants
- Gabapentin

See the Data Submitter's Guide for a full list.

Start submitting today!





ILPMP.org

Step 1: Register to become a Data Submitter 
a https://rxsubmit-il.logicoy.com/

Step 2: Download the Illinois Data Submitter's Guide

For Naloxone submission, the ILPMP requires NPI, and DEA number if applicable.

# **ILPMP.ORG & PMPnow Monthly Data**

# WEBSITE DATA JUNE 2023





4,614

NEW USERS IN JUNE



92,235

TOTAL USERS



69,851

TOTAL ILPMP PRESCRIBER USERS



861,555

TOTAL ILPMP WEBSITE REQUESTS



1,584

TOTAL PMPNOW CONNECTIONS





10,398,508

TOTAL PMPNOW REQUESTS

#### **Contact Information**

If you have questions about the information that appears in this update or suggestions for future content, please email **dhs.pmp@illinois.gov**. Visit **www.ilpmp.org** for more information.





The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality

Illinois Prescription Monitoring Program | 401 North Fourth Street, Springfield, IL 62702 www.ilpmp.org

Unsubscribe brittany.queen2@illinois.gov

 $\frac{ \mbox{ Update Profile } | \mbox{Constant Contact Data}}{\mbox{Notice}}$ 

Sent bydhs.pmp@illinois.govpowered by

